NanoSep MF centrifugal filtration device for sample pre-treatment analysis
NanoSep MF centrifugal filtration device
Ideal for precise filtration of small amounts of analytical samples!
The NanoSep MF centrifugal filtration device is a 1.5 mL tube-style filter equipped with wwPTFE (highly hydrophilic PTFE). It is useful for the pretreatment of small amounts of analytical samples, capable of high-speed rotation at 14,000xg, allowing for rapid sample filtration. Features: ● Rapid sample processing: Designed for use in centrifuges, it can simultaneously centrifuge multiple samples. ● Versatile membrane filter: Built with a wwPTFE (highly hydrophilic PTFE) membrane, it has chemical resistance to aqueous solutions, organic solvents, and corrosive organic solvents. ● High recovery rate: The wwPTFE membrane has low protein adsorption, effectively removing unwanted particles from samples while achieving high recovery rates of valuable proteins. ● Low leachables: HPLC-grade centrifuges have been proven to have low levels of leachables that absorb UV. ● Leak-free structure: With a unique sealing technology, it guarantees no sample leakage by avoiding the use of potentially contaminating materials such as O-rings or adhesives.
Inquire About This Product
basic information
The NanoSep MF centrifugal filtration device is a 1.5 mL tube-type centrifugal filtration filter. It can be used for pre-filtration of small amounts of analytical samples. wwPTFE is a membrane that can be used with both aqueous solutions and organic solvents, and it has excellent chemical resistance. Two pore sizes are available: 0.2 µm and 0.45 µm.
Price range
Delivery Time
Applications/Examples of results
Application ■ Sample Preprocessing - Removes microparticles from small samples before UHPLC and HPLC analysis using pore sizes of 0.2μm and 0.45μm. ■ Removal of precipitates such as metals, polymers, and plasma. ■ Removal of cells from media before analysis. ■ Applications requiring maximum recovery of filtrate or retained liquid from small samples.
Company information
Cytiva and Pall Life Sciences have merged their businesses and will officially launch under the "Cytiva" brand on May 1, 2023. Under our mission of "Advancing therapies, faster," we will integrate both organizations and focus even more on supporting the development and manufacturing of better therapies for patients as a stronger global provider of technologies and services. The new Cytiva will offer a broader and deeper expertise and a rich lineup of products and services to better support various customers involved in research and the manufacturing and development of biopharmaceuticals, enabling them to deliver therapies to patients more quickly, from discovery to delivery. With a rich history spanning several hundred years, Pall Life Sciences and Cytiva, as part of the Danaher Group, will continue to unite to provide better services to our customers.
![[Information] Security by Design](https://image.mono.ipros.com/public/product/image/46a/2000921290/IPROS60632797019289942922.png?w=280&h=280)
![[Research Material] The Global Market for Transcatheter Aortic Valve Replacement (TAVR)](https://image.mono.ipros.com/public/product/image/bb6/2001471733/IPROS04128926101506708288.jpeg?w=280&h=280)
